Our FAERS analysis showed PD‐L1 inhibitors were more associated with immune‐mediated liver disease and hepatic failure, whereas PD‐1 inhibitors were linked to hepatitis and liver abnormalities, underscoring the need for drug‐specific monitoring. This evidence concerns the gene CD274 and hepatitis A virus infection.